TSE:MDNAMedicenna Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$5.47 -0.02 (-0.36 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's RangeC$5.35Now: C$5.47▼C$5.5550-Day RangeC$4.87MA: C$5.31▼C$6.0252-Week RangeC$0.94Now: C$5.47▼C$7.25Volume46,360 shsAverage Volume120,357 shsMarket CapitalizationC$266.93 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$4.00, Medicenna Therapeutics has a potential downside of 26.9% from its current price of C$5.47.Amount of Analyst CoverageMedicenna Therapeutics has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMedicenna Therapeutics has received 73 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedicenna Therapeutics has received 80 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedicenna Therapeutics has received 52.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medicenna Therapeutics and other stocks. Vote “Outperform” if you believe MDNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -21.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicenna Therapeutics has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.78 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:MDNA Previous Symbol CUSIPN/A CIKN/A Webwww.medicenna.com Phone+1-403-6807898Debt Debt-to-Equity Ratio0.19 Current Ratio20.85 Quick Ratio20.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.83 per share Price / Cash Flow6.58 Book ValueC$0.77 per share Price / Book7.09Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares48,798,000Market CapC$266.93 million Next Earnings DateN/A OptionableNot Optionable C$5.47 -0.02 (-0.36 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MDNA News and Ratings via Email Sign-up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Medicenna Therapeutics (TSE:MDNA) Frequently Asked Questions How has Medicenna Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Medicenna Therapeutics' stock was trading at C$3.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDNA stock has increased by 81.1% and is now trading at C$5.47. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Medicenna Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Medicenna Therapeutics. What price target have analysts set for MDNA? 1 equities research analysts have issued twelve-month price targets for Medicenna Therapeutics' stock. Their forecasts range from C$4.00 to C$4.00. On average, they expect Medicenna Therapeutics' stock price to reach C$4.00 in the next year. This suggests that the stock has a possible downside of 26.9%. View analysts' price targets for Medicenna Therapeutics. Has Medicenna Therapeutics been receiving favorable news coverage? News articles about MDNA stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medicenna Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Medicenna Therapeutics. Who are some of Medicenna Therapeutics' key competitors? Some companies that are related to Medicenna Therapeutics include Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), Trillium Therapeutics (TRIL), Nkarta (ANNX), PureTech Health (PRTC), Oxford BioMedica (OXB), Aptose Biosciences (APS), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), CEL-SCI (CVM), Biotest (BIO), Ibio (IBIO), Neptune Wellness Solutions (NEPT), Inventiva (IVA) and IMV (IMV). View all competitors. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include AbbVie (ABBV), Allogene Therapeutics (ALLO), Aptose Biosciences (APTO), ARC Resources (ARX), Antibe Therapeutics (ATE), Aurinia Pharmaceuticals (AUPH), Birchcliff Energy (BIR), CROWN CASTLE IN/SH SH (CCI), CVS Health (CVS) and Dream Industrial Real Estate Invest Trst (DIR.UN). Who are Medicenna Therapeutics' key executives? Medicenna Therapeutics' management team includes the following people: Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 62)Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 62)Ms. Elizabeth Williams CPA, CA, CFO & Corp. Sec. (Age 41)Dr. Shafique Fidai Ph.D., Head of Discovery & Corp. Devel.Dr. John Sampson M.D., Ph.D., MBA, Chief Clinical Advisor What is Medicenna Therapeutics' stock symbol? Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA." How do I buy shares of Medicenna Therapeutics? Shares of MDNA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Medicenna Therapeutics' stock price today? One share of MDNA stock can currently be purchased for approximately C$5.47. How big of a company is Medicenna Therapeutics? Medicenna Therapeutics has a market capitalization of C$266.93 million. What is Medicenna Therapeutics' official website? The official website for Medicenna Therapeutics is www.medicenna.com. How can I contact Medicenna Therapeutics? Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company can be reached via phone at +1-403-6807898. This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
